B. Riley restated their buy rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note released on Monday, TipRanks reports. They currently have a $97.00 price target on the biopharmaceutical company’s stock. B. Riley also issued estimates for Intercept Pharmaceuticals’ Q2 2020 earnings at ($3.07) EPS, Q3 2020 earnings at ($3.23) EPS, Q4 2020 earnings at ($3.46) EPS, FY2020 earnings at ($12.63) EPS, FY2021 earnings at ($13.37) EPS, FY2022 earnings at ($4.88) EPS, FY2023 earnings at $0.13 EPS and FY2024 earnings at $6.14 EPS.
ICPT has been the subject of several other research reports. Raymond James cut shares of Intercept Pharmaceuticals from an outperform rating to a market perform rating in a report on Monday. Wells Fargo & Co cut Intercept Pharmaceuticals from an overweight rating to an equal weight rating and decreased their target price for the company from $146.00 to $46.00 in a research report on Monday. HC Wainwright started coverage on Intercept Pharmaceuticals in a research note on Thursday, June 25th. They set a neutral rating and a $92.00 price target on the stock. Bank of America began coverage on Intercept Pharmaceuticals in a research note on Thursday, March 5th. They issued a neutral rating and a $111.00 price objective for the company. Finally, Robert W. Baird reissued a buy rating and issued a $227.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, May 22nd. Eighteen analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $74.13.
Shares of NASDAQ:ICPT opened at $47.09 on Monday. Intercept Pharmaceuticals has a 52 week low of $44.50 and a 52 week high of $125.00. The company’s 50 day moving average is $77.14 and its two-hundred day moving average is $87.38. The company has a market cap of $1.51 billion, a PE ratio of -4.39 and a beta of 1.79. The company has a current ratio of 4.19, a quick ratio of 4.19 and a debt-to-equity ratio of 10.32.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the transaction, the director now directly owns 19,433 shares in the company, valued at $1,644,031.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last three months, insiders have sold 595,817 shares of company stock worth $50,405,516. 23.70% of the stock is owned by insiders.
A number of large investors have recently bought and sold shares of ICPT. Victory Capital Management Inc. grew its holdings in Intercept Pharmaceuticals by 6.7% during the 4th quarter. Victory Capital Management Inc. now owns 3,895 shares of the biopharmaceutical company’s stock valued at $483,000 after buying an additional 244 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its position in Intercept Pharmaceuticals by 1.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 163,811 shares of the biopharmaceutical company’s stock worth $20,300,000 after acquiring an additional 3,125 shares during the last quarter. National Asset Management Inc. purchased a new position in shares of Intercept Pharmaceuticals during the 4th quarter worth about $233,000. Envestnet Asset Management Inc. acquired a new stake in shares of Intercept Pharmaceuticals in the fourth quarter worth approximately $299,000. Finally, EAM Investors LLC purchased a new stake in Intercept Pharmaceuticals in the fourth quarter valued at approximately $1,575,000. Hedge funds and other institutional investors own 76.46% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Further Reading: What causes a recession?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.